Please welcome Dr Matthew Albrecht, an NHMRC Early Career Research Fellow who extends CHIRI’s expertise in preclinical and clinical neurological disorders theme. Matthew graduated from his PhD (Pharmacology, UWA) in 2012 studying the effects of dexamphetamine on electrophysiology, phenomenology, and behaviour associated with schizophrenia in human subjects.  He then joined Curtin University as a postdoctoral researcher, investigating relationships between genetics, biomarkers, and environmental factors on cognitive performance in older adults and in people with an autism spectrum disorder.  He also furthered his knowledge in quantitative methods, notably all things Bayesian and hierarchical. In 2014, he did further postdoctoral work at the Maryland Psychiatric Research Centre (MPRC; University of Maryland, Baltimore). There began an induction into computational modelling of behaviour and more electrophysiology in patients with schizophrenia/psychotic disorder. Soon after, he was awarded an NHMRC Early Career Fellowship and spent a bit longer at the MPRC continuing human psychosis research, while adding preclinical rodent electrophysiology experiments investigating neurodevelopmental models of schizophrenia. He is currently spending the remainder of his Fellowship in the laboratory of John Mamo, getting insights into brain vascular physiology and rodent cognitive assessment.